Catalent acquires Erytech plant in New Jersey

Catalent, the global leader enabling biopharmaceutical, cellular, genetics and consumer health partners to optimize the development, launch and delivery of better treatments to patients across multiple modalities, has acquired from Erytech Pharma its cutting-edge cell commercial-scale therapeutics manufacturing plant in Princeton, NJ, for $44.5 million. The agreement includes an exclusive long-term supply agreement with Catalent to support Erytech’s lead product candidate, eryaspase (GRASPA®), a product derived from red blood cells, currently in advanced development for the treatment of acute lymphoblastic leukemia.

The 30,900 square foot facility is located in University Square Campus Park and houses 16 suites positioned for the production of GMP-compliant products, as well as analytical, quality control and microbiological testing laboratories. The site will become a strategic campus for the development, as well as the clinical and commercial scale manufacturing of cell therapies, and is located near Catalent’s facilities around Baltimore, Maryland, where the company develops and manufactures vectors viral and plasmid DNA. . It will also work in conjunction with Catalent’s existing US clinical-scale cell therapy facility in Houston, Texas.

Along with the acquisition, Catalent agreed to lease terms for an adjacent 23,000 square foot building that could be used for additional lab or cGMP capabilities, and another on-campus building for potential future expansions. All site personnel will be transferred to Catalent employment, and Catalent is developing its plans for its future recruitment needs. Under the supply agreement, Catalent will continue to manufacture eryaspase (GRASPA) at the site. It will also support the development of Erytech’s pipeline of therapeutic products based on encapsulated red blood cells for severe forms of cancer and orphan diseases.

“This acquisition is strategically important to Catalent’s commitment to supporting the development and clinical and commercial supply of cell therapies to meet rapidly growing demand,” said Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy. “The talented and experienced staff already employed at the facility, the capabilities available to them, and the ability to quickly add additional capabilities at the same site, allow Catalent to grow rapidly to create a US campus and center for excellence for the development of cell therapy. and manufacturing that will serve customers around the world.

Catalent’s Cell and Gene Therapy Network includes six US facilities in Maryland and Texas, a European Center of Excellence in Belgium and its Cell Innovation Facility in Germany. These sites offer a range of small and large scale clinical and commercial manufacturing, as well as fill/finish capabilities.

Comments are closed.